Bacteriophage最新文献_第9页

Bacteriophages lytic for Salmonella rapidly reduce Salmonella contamination on glass and stainless steel surfaces. 沙门氏菌噬菌体可迅速减少玻璃和不锈钢表面的沙门氏菌污染。

Bacteriophage Pub Date : 2013-07-01 Epub Date: 2013-07-26 DOI: 10.4161/bact.25697

Joelle Woolston, Adam R Parks, Tamar Abuladze, Bradley Anderson, Manrong Li, Chandi Carter, Leigh Farris Hanna, Serena Heyse, Duane Charbonneau, Alexander Sulakvelidze

{"title":"Bacteriophages lytic for Salmonella rapidly reduce Salmonella contamination on glass and stainless steel surfaces.","authors":"Joelle Woolston, Adam R Parks, Tamar Abuladze, Bradley Anderson, Manrong Li, Chandi Carter, Leigh Farris Hanna, Serena Heyse, Duane Charbonneau, Alexander Sulakvelidze","doi":"10.4161/bact.25697","DOIUrl":"https://doi.org/10.4161/bact.25697","url":null,"abstract":"A cocktail of six lytic bacteriophages, SalmoFresh™, significantly (p < 0.05) reduced the number of surface-applied Salmonella Kentucky and Brandenburg from stainless steel and glass surfaces by > 99% (2.1–4.3 log). Both strains were susceptible to SalmoFresh™ in the spot-test assay. Conversely, SalmoFresh™ was unable to reduce surface contamination with a Salmonella Paratyphi B strain that was not susceptible to the phage cocktail in the spot-test assay. However, by replacing two SalmoFresh™ component phages with two new phages capable of lysing the Paratyphi B strain in the spot-test assay, the target range of the cocktail was shifted to include the Salmonella Paratyphi B strain. The modified cocktail, SalmoLyse™, was able to significantly (p < 0.05) reduce surface contamination of the Paratyphi B strain by > 99% (2.1–4.1 log). The data show that both phage cocktails were effective in significantly reducing the levels of Salmonella on hard surfaces, provided the contaminating strains were susceptible in the spot-test (i.e., spot-test susceptibility was indicative of efficacy in subsequent surface decontamination studies). The data also support the concept that phage preparations can be customized to meet the desired antibacterial application.","PeriodicalId":8686,"journal":{"name":"Bacteriophage","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4161/bact.25697","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31862928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Life in Science: Armin Dale Kaiser. 《科学生活》:阿明·戴尔·凯泽。

Bacteriophage Pub Date : 2013-07-01 Epub Date: 2013-06-28 DOI: 10.4161/bact.25589

Armin Dale Kaiser

引用次数: 0

Innate and acquired bacteriophage-mediated immunity. 先天和获得性噬菌体介导免疫。

Bacteriophage Pub Date : 2013-07-01 Epub Date: 2013-07-29 DOI: 10.4161/bact.25857

Jeremy J Barr, Merry Youle, Forest Rohwer

引用次数: 66

Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128: Comparison to recombinant lysostaphin. 噬菌体衍生的嵌合重组葡萄球菌溶解蛋白P128的性质和突变研究:与重组溶葡萄球菌蛋白的比较。

Bacteriophage Pub Date : 2013-07-01 Epub Date: 2013-10-02 DOI: 10.4161/bact.26564

Sanjeev Rajagopalan Saravanan, Vivek Daniel Paul, Shilpa George, Sudarson Sundarrajan, Nirmal Kumar, Madhavi Hebbur, Naveen Kumar, Ananda Veena, Uma Maheshwari, Chemira Biddappa Appaiah, Muralidharan Chidambaran, Anuradha Gopal Bhat, Sukumar Hariharan, Sriram Padmanabhan

{"title":"Properties and mutation studies of a bacteriophage-derived chimeric recombinant staphylolytic protein P128: Comparison to recombinant lysostaphin.","authors":"Sanjeev Rajagopalan Saravanan, Vivek Daniel Paul, Shilpa George, Sudarson Sundarrajan, Nirmal Kumar, Madhavi Hebbur, Naveen Kumar, Ananda Veena, Uma Maheshwari, Chemira Biddappa Appaiah, Muralidharan Chidambaran, Anuradha Gopal Bhat, Sukumar Hariharan, Sriram Padmanabhan","doi":"10.4161/bact.26564","DOIUrl":"https://doi.org/10.4161/bact.26564","url":null,"abstract":"P128 is a chimeric anti-staphylococcal protein having a catalytic domain from a Staphylococcus bacteriophage K tail associated structural protein and a cell wall targeting domain from the Staphylococcus bacteriocin-lysostaphin. In this study, we disclose additional properties of P128 and compared the same with lysostaphin. While lysostaphin was found to get inactivated by heat and was inactive on its parent strain S. simulans biovar staphylolyticus, P128 was thermostable and was lytic towards S. simulans biovar staphylolyticus demonstrating a difference in their mechanism of action. Selected mutation studies of the catalytic domain of P128 showed that arginine and cysteine, at 40th and 76th positions respectively, are critical for the staphylolytic activity of P128, although these amino acids are not conserved residues. In comparison to native P128, only the R40S mutant (P301) was catalytically active on zymogram gel and had a similar secondary structure, as assessed by circular dichroism analysis and in silico modeling with similar cell binding properties. Mutation of the arginine residue at 40th position of the P128 molecule caused dramatic reduction in the Vmax (∆OD600 [mg/min]) value (nearly 270 fold) and the recombinant lysostaphin also showed lesser Vmax value (nearly 1.5 fold) in comparison to the unmodified P128 protein. The kinetic parameters such as apparent Km (KmAPP) and apparent Kcat (KcatAPP) of the native P128 protein also showed significant differences in comparison to the values observed for P301 and lysostaphin.","PeriodicalId":8686,"journal":{"name":"Bacteriophage","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.4161/bact.26564","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31881535","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 14

Listeria phages: Genomes, evolution, and application. 李斯特菌噬菌体：基因组、进化和应用。

Bacteriophage Pub Date : 2013-07-01 Epub Date: 2013-10-24 DOI: 10.4161/bact.26861

Jochen Klumpp, Martin J Loessner

引用次数: 0

Life in Science: Richard Calendar. 科学生活:Richard Calendar。

Bacteriophage Pub Date : 2013-04-01 DOI: 10.4161/bact.25516

Richard Calendar

引用次数: 1

What are the limitations on the wider therapeutic use of phage? 噬菌体在更广泛的治疗用途方面有哪些限制？

Bacteriophage Pub Date : 2013-04-01 DOI: 10.4161/bact.24872

Alexandra Henein

{"title":"What are the limitations on the wider therapeutic use of phage?","authors":"Alexandra Henein","doi":"10.4161/bact.24872","DOIUrl":"10.4161/bact.24872","url":null,"abstract":"Bacterial resistance to antibiotics poses a serious health threat. Since research into new antibiotics is not progressing at the same rate as the development of bacterial resistance, widespread calls for alternatives to antibiotics have been made. Phage therapy is an ideal alternative candidate to be investigated. However the success of phage therapy may be hampered by a lack of investment support from large pharmaceutical companies, due to their narrow spectrum of activity in antibiotics, very large costs associated with clinical trials of the variety of phages needed, and regulatory requirements remaining unclear. Intellectual property is difficult to secure for therapeutic phage products for a variety of reasons, and patenting procedures vary widely between the US and the EU. Consequently, companies are more likely to invest in phage products for decontamination or veterinary use, rather than clinical use in humans. Some still raise questions as to the safety of phage therapy overall, suggesting the possibility of cytotoxicity and immunogenicity, depending on the phage preparation and route. On the other hand, with patients dying because of infections untreatable with conventional antibiotics, the question arises as to whether it is ethical not to pursue phage therapy more diligently. A paradigm shift about how phage therapy is perceived is required, as well as more rigorous proof of efficacy in the form of clinical trials of existing medicinal phage products. Phage therapy potential may be fulfilled in the meantime by allowing individual preparations to be used on a named-patient basis, with extensive monitoring and multidisciplinary team input. The National Health Service and academia have a role in carrying out clinical phage research, which would be beneficial to public health, but not necessarily financially rewarding.","PeriodicalId":8686,"journal":{"name":"Bacteriophage","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/02/c2/bact-3-e24872.PMC3821673.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31862922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Upcoming meetings 即将到来的会议

Bacteriophage Pub Date : 2013-04-01 DOI: 10.1111/1744-9987.12133

Alexander Sulakvelidze

引用次数: 0

Lytic bacteriophages: Potential interventions against enteric bacterial pathogens on produce. 噬菌体：对农产品肠道细菌病原体的潜在干预措施。

Bacteriophage Pub Date : 2013-04-01 DOI: 10.4161/bact.25518

Manan Sharma

{"title":"Lytic bacteriophages: Potential interventions against enteric bacterial pathogens on produce.","authors":"Manan Sharma","doi":"10.4161/bact.25518","DOIUrl":"10.4161/bact.25518","url":null,"abstract":"Foodborne illnesses resulting from the consumption of produce commodities contaminated with enteric pathogens continue to be a significant public health issue. Lytic bacteriophages may provide an effective and natural intervention to reduce bacterial pathogens on fresh and fresh-cut produce commodities. The use of multi-phage cocktails specific for a single pathogen has been most frequently assessed on produce commodities to minimize the development of bacteriophage insensitive mutants (BIM) in target pathogen populations. Regulatory approval for the use of several lytic phage products specific for bacterial pathogens such as Escherichia coli O157:H7, Salmonella spp. and Listeria monocytogenes in foods and on food processing surfaces has been granted by various agencies in the US and other countries, possibly allowing for the more widespread use of bacteriophages in the decontamination of fresh and minimally processed produce. Research studies have shown lytic bacteriophages specific for E. coli O157:H7, Salmonella spp. and Listeria monocytogenes have been effective in reducing pathogen populations on leafy greens, sprouts and tomatoes.","PeriodicalId":8686,"journal":{"name":"Bacteriophage","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2013-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/81/06/bact-3-e25518.PMC3821672.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"31862925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Enzymatic characterization of a lysin encoded by bacteriophage EL. 噬菌体EL编码的溶解酶的酶学特性。

Bacteriophage Pub Date : 2013-04-01 DOI: 10.4161/bact.25449

Diana A Tafoya, Zacariah L Hildenbrand, Nadia Herrera, Sudheer K Molugu, Vadim V Mesyanzhinov, Konstantin A Miroshnikov, Ricardo A Bernal

引用次数: 4